Please login to the form below

Not currently logged in
Email:
Password:

sotagliflozin

This page shows the latest sotagliflozin news and features for those working in and with pharma, biotech and healthcare.

Success for AZ, setback for Sanofi in type 1 diabetes

Success for AZ, setback for Sanofi in type 1 diabetes

Sanofi has been less fortunate with its US marketing application for Lexicon Pharma-partnered dual SGLT1/SGLT2 inhibitor Zynquista (sotagliflozin) alongside insulin in type 1 diabetes, however, as this was rejected

Latest news

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2015 Deal Watch November 2015

    Staying with diabetes, so strategically important, Sanofi put in place a collaboration with Lexicon Pharmaceuticals for sotagliflozin (LX4211), an oral treatment for type 1 and type 2 diabetes. ... 2, 075. Lexicon Pharmaceuticals. Sanofi. Collaboration,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics